Pharmacokinetics and Catabolism of [3H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate

Abstract 3916: Relationship of guanylyl cyclase C (GCC) expression and efficacy of TAK-164, a GCC-targeted antibody-drug conjugate in a panel of 68 subcutaneous HuPrime colorectal cancer PDX models

10.1158/1538-7445.am2018-3916 ◽

2018 ◽

Cited By ~ 1

Author(s):

Erik M. Koenig ◽

Cong Li ◽

Huyuan Yang ◽

Andy Zhu ◽

Pooja Shah ◽

...

Keyword(s):

Colorectal Cancer ◽

Guanylyl Cyclase ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Relationship Of ◽

Pdx Models ◽

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

Investigational New Drugs ◽

10.1007/s10637-017-0439-y ◽

2017 ◽

Vol 35 (2) ◽

pp. 235-241 ◽

Cited By ~ 8

Author(s):

Khaldoun Almhanna ◽

Maria Luisa Limon Miron ◽

David Wright ◽

Antonio Cubillo Gracian ◽

Richard A. Hubner ◽

...

Keyword(s):

Phase Ii ◽

Guanylyl Cyclase ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Abstract PR12: MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC), demonstrates antitumor activity alone and in combination with gemcitabine in human pancreatic cancer xenograft models expressing GCC.

10.1158/1535-7163.targ-13-pr12 ◽

2013 ◽

Cited By ~ 4

Author(s):

Julie Zhang ◽

Melissa Gallery ◽

Tim Wyant ◽

Brad Stringer ◽

Mark Manfredi ◽

...

Keyword(s):

Pancreatic Cancer ◽

Antitumor Activity ◽

Guanylyl Cyclase ◽

Human Pancreatic Cancer ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Xenograft Models ◽

Class Antibody ◽

Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCC

Annals of Oncology ◽

10.1093/annonc/mdu193.9 ◽

2014 ◽

Vol 25 ◽

pp. ii108 ◽

Cited By ~ 1

Author(s):

J.E. Faris ◽

C. Cruz ◽

K. Almhanna ◽

W. Messersmith ◽

J. Rodon ◽

...

Keyword(s):

Phase I ◽

Guanylyl Cyclase ◽

Phase I Study ◽

Adult Patients ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Abstract 4649: Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti- guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models

10.1158/1538-7445.am2014-4649 ◽

2014 ◽

Cited By ~ 1

Author(s):

Shu-Wen Teng ◽

Christopher Zopf ◽

Johnny Yang ◽

Brad Stringer ◽

Julie Zhang ◽

...

Keyword(s):

Guanylyl Cyclase ◽

Optimal Schedule ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Xenograft Models ◽

Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies

Annals of Oncology ◽

10.1093/annonc/mdt202.30 ◽

2013 ◽

Vol 24 ◽

pp. iv36 ◽

Cited By ~ 2

Author(s):

Wells Messersmith ◽

Khaldoun Almhanna ◽

Jordi Rodon ◽

Cristina Cruz ◽

David Ryan ◽

...

Keyword(s):

Guanylyl Cyclase ◽

Human Study ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Class Antibody ◽

Abstract CT117: A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)

10.1158/1538-7445.am2016-ct117 ◽

2016 ◽

Author(s):

Khaldoun Almhanna ◽

David Wright ◽

Teresa Macarulla Mercadé ◽

Jean-Luc Van Laethem ◽

Antonio Cubillo Gracian ◽

...

Keyword(s):

Pancreatic Adenocarcinoma ◽

Phase Ii ◽

Guanylyl Cyclase ◽

Phase Ii Trial ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Investigational New Drugs ◽

10.1007/s10637-017-0473-9 ◽

2017 ◽

Vol 35 (5) ◽

pp. 634-641 ◽

Cited By ~ 8

Author(s):

Khaldoun Almhanna ◽

David Wright ◽

Teresa Macarulla Mercade ◽

Jean-Luc Van Laethem ◽

Antonio Cubillo Gracian ◽

...

Keyword(s):

Pancreatic Adenocarcinoma ◽

Phase Ii ◽

Guanylyl Cyclase ◽

Phase Ii Study ◽

Guanylyl Cyclase C ◽

Antibody Drug Conjugate ◽

Metastatic Pancreatic Adenocarcinoma ◽

Previously Treated Patients ◽

Previously Treated ◽

Antibody–drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies

Pharmacology & Therapeutics ◽

10.1016/j.pharmthera.2016.10.007 ◽

2017 ◽

Vol 170 ◽

pp. 8-13 ◽

Cited By ~ 4

Author(s):

Khaldoun Almhanna ◽

Gopi K. Prithviraj ◽

Petter Veiby ◽

Thea Kalebic

Keyword(s):

Guanylyl Cyclase ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-15-2474 ◽

2016 ◽

Vol 22 (20) ◽

pp. 5049-5057 ◽

Cited By ~ 17

Author(s):

Khaldoun Almhanna ◽

Thea Kalebic ◽

Cristina Cruz ◽

Jason E. Faris ◽

David P. Ryan ◽

...

Keyword(s):

Phase I ◽

Guanylyl Cyclase ◽

Phase I Study ◽

Adult Patients ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽